Companies › LISCure Biosciences
1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LB-P8 Live biotherapeutic product (probiotic) | – | Phase 2 | Primary Sclerosing Cholangitis (PSC) | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06699121 | LB-P8 | Phase 2 | Primary Sclerosing Cholangitis (PSC) | Immunology | Mar 2028 |
No annotated target.
–
Calixis Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Qifeng Zhang Topadur Pharma Leadingtac Pharmaceutical (Shaoxing)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.